Radius Health Inc (RDUS) Major Shareholder Acquires $2,466,988.37 in Stock

Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech bought 61,721 shares of the stock in a transaction that occurred on Wednesday, March 15th. The shares were purchased at an average cost of $39.97 per share, with a total value of $2,466,988.37. Following the purchase, the insider now directly owns 4,415,930 shares of the company’s stock, valued at $176,504,722.10. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Radius Health Inc (NASDAQ:RDUS) opened at 38.22 on Tuesday. Radius Health Inc has a 12-month low of $28.00 and a 12-month high of $59.88. The firm has a 50-day moving average of $42.64 and a 200-day moving average of $47.09. The firm’s market capitalization is $1.65 billion.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.34) by $0.12. During the same quarter in the previous year, the firm posted ($0.77) earnings per share. Equities analysts anticipate that Radius Health Inc will post ($4.06) earnings per share for the current year.

var userip;Your IP Address: document.write(userip);

Institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in Radius Health by 4.3% in the second quarter. Royal Bank of Canada now owns 836,118 shares of the biopharmaceutical company’s stock worth $30,729,000 after buying an additional 34,694 shares in the last quarter. FNY Managed Accounts LLC bought a new position in Radius Health during the third quarter worth approximately $297,000. Hamilton Lane Advisors LLC bought a new position in Radius Health during the third quarter worth approximately $2,708,000. Nationwide Fund Advisors boosted its position in Radius Health by 6.0% in the third quarter. Nationwide Fund Advisors now owns 24,670 shares of the biopharmaceutical company’s stock worth $1,334,000 after buying an additional 1,400 shares in the last quarter. Finally, Lebenthal Lisanti Capital Growth LLC boosted its position in Radius Health by 39.4% in the third quarter. Lebenthal Lisanti Capital Growth LLC now owns 18,095 shares of the biopharmaceutical company’s stock worth $979,000 after buying an additional 5,110 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on the stock. Maxim Group set a $24.00 target price on shares of Radius Health and gave the stock a “sell” rating in a research note on Saturday, March 11th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Radius Health in a research note on Saturday, March 11th. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Saturday, March 11th. Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Saturday, February 25th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $40.00 target price on shares of Radius Health in a research note on Friday, February 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. Radius Health has an average rating of “Hold” and a consensus target price of $56.00.

About Radius Health

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.